Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
BRIDGEWATER, N.J. and NETANYA, Israel Dec. 10, 2024 /PRNewswire/ -- Theranica , a prescribed neuromodulation therapeutics company, today announced significant milestones in 2024, including a recently released study highlighting barriers and preferences when treating migraine at school. Other achievements this year include an expanded age indication from the FDA, clearing the treatment for use in patients aged eight and older; the appointment of a new chief medical officer; and improved access and affordability with insurance coverage reaching 30 million people. Addressing Migraine at School with the REN Wearable A study published in Children , a peer-reviewed publication highlights the challenges children and adolescents face in treating migraine at school, emphasizing key barriers such as lack of access to treatment, inconvenience to treat in class, and social stigma. In the study, 64.2% of the 332 young participants reported having to leave the classroom to receive drug treatme
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at Nomura from a "buy" rating to a "neutral" rating.MarketBeat
- Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- Heparin Market to Grow by USD 3.34 Billion (2024-2028), Driven by Coagulation Disorder Prevalence and AI Impacting Market Trends - Technavio [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 11/6/24 - Beat
RDY
Sec Filings
- 12/20/24 - Form 6-K
- 12/6/24 - Form 6-K
- 12/6/24 - Form 6-K
- RDY's page on the SEC website